These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clonal genotype and population structure inference from single-cell tumor sequencing. Roth A; McPherson A; Laks E; Biele J; Yap D; Wan A; Smith MA; Nielsen CB; McAlpine JN; Aparicio S; Bouchard-Côté A; Shah SP Nat Methods; 2016 Jul; 13(7):573-6. PubMed ID: 27183439 [TBL] [Abstract][Full Text] [Related]
3. clonealign: statistical integration of independent single-cell RNA and DNA sequencing data from human cancers. Campbell KR; Steif A; Laks E; Zahn H; Lai D; McPherson A; Farahani H; Kabeer F; O'Flanagan C; Biele J; Brimhall J; Wang B; Walters P; ; Bouchard-Côté A; Aparicio S; Shah SP Genome Biol; 2019 Mar; 20(1):54. PubMed ID: 30866997 [TBL] [Abstract][Full Text] [Related]
4. Somatic mutation detection and classification through probabilistic integration of clonal population information. Dorri F; Jewell S; Bouchard-Côté A; Shah SP Commun Biol; 2019; 2():44. PubMed ID: 30729182 [TBL] [Abstract][Full Text] [Related]
5. High level of chromosomal aberration in ovarian cancer genome correlates with poor clinical outcome. Cope L; Wu RC; Shih IeM; Wang TL Gynecol Oncol; 2013 Mar; 128(3):500-5. PubMed ID: 23200914 [TBL] [Abstract][Full Text] [Related]
6. A data science approach for the classification of low-grade and high-grade ovarian serous carcinomas. Lin S; Wang C; Zarei S; Bell DA; Kerr SE; Runger GC; Kocher JA BMC Genomics; 2018 Nov; 19(1):841. PubMed ID: 30482155 [TBL] [Abstract][Full Text] [Related]
7. Histotype-specific copy-number alterations in ovarian cancer. Huang RY; Chen GB; Matsumura N; Lai HC; Mori S; Li J; Wong MK; Konishi I; Thiery JP; Goh L BMC Med Genomics; 2012 Oct; 5():47. PubMed ID: 23078675 [TBL] [Abstract][Full Text] [Related]
8. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. Bashashati A; Ha G; Tone A; Ding J; Prentice LM; Roth A; Rosner J; Shumansky K; Kalloger S; Senz J; Yang W; McConechy M; Melnyk N; Anglesio M; Luk MT; Tse K; Zeng T; Moore R; Zhao Y; Marra MA; Gilks B; Yip S; Huntsman DG; McAlpine JN; Shah SP J Pathol; 2013 Sep; 231(1):21-34. PubMed ID: 23780408 [TBL] [Abstract][Full Text] [Related]
9. Functional analysis of the 1p34.3 risk locus implicates GNL2 in high-grade serous ovarian cancer. Nakamura K; Reid BM; Chen A; Chen Z; Goode EL; Permuth JB; Teer JK; Tyrer J; Yu X; Kanetsky PA; Pharoah PD; Gayther SA; Sellers TA; Lawrenson K; Karreth FA Am J Hum Genet; 2022 Jan; 109(1):116-135. PubMed ID: 34965383 [TBL] [Abstract][Full Text] [Related]
10. ESRRA-C11orf20 is a recurrent gene fusion in serous ovarian carcinoma. Salzman J; Marinelli RJ; Wang PL; Green AE; Nielsen JS; Nelson BH; Drescher CW; Brown PO PLoS Biol; 2011 Sep; 9(9):e1001156. PubMed ID: 21949640 [TBL] [Abstract][Full Text] [Related]
11. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. McPherson A; Roth A; Laks E; Masud T; Bashashati A; Zhang AW; Ha G; Biele J; Yap D; Wan A; Prentice LM; Khattra J; Smith MA; Nielsen CB; Mullaly SC; Kalloger S; Karnezis A; Shumansky K; Siu C; Rosner J; Chan HL; Ho J; Melnyk N; Senz J; Yang W; Moore R; Mungall AJ; Marra MA; Bouchard-Côté A; Gilks CB; Huntsman DG; McAlpine JN; Aparicio S; Shah SP Nat Genet; 2016 Jul; 48(7):758-67. PubMed ID: 27182968 [TBL] [Abstract][Full Text] [Related]
12. Inferring copy number and genotype in tumour exome data. Amarasinghe KC; Li J; Hunter SM; Ryland GL; Cowin PA; Campbell IG; Halgamuge SK BMC Genomics; 2014 Aug; 15(1):732. PubMed ID: 25167919 [TBL] [Abstract][Full Text] [Related]
13. Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer? Vineyard MA; Daniels MS; Urbauer DL; Deavers MT; Sun CC; Boerwinkle E; Bodurka DC; Gershenson DM; Crawford J; Lu KH Gynecol Oncol; 2011 Feb; 120(2):229-32. PubMed ID: 21126756 [TBL] [Abstract][Full Text] [Related]
14. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver. Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A; Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818 [TBL] [Abstract][Full Text] [Related]
15. Intraindividual genomic heterogeneity of high-grade serous carcinoma of the ovary and clinical utility of ascitic cancer cells for mutation profiling. Choi YJ; Rhee JK; Hur SY; Kim MS; Lee SH; Chung YJ; Kim TM; Lee SH J Pathol; 2017 Jan; 241(1):57-66. PubMed ID: 27741368 [TBL] [Abstract][Full Text] [Related]
16. Involvement of ATMIN-DYNLL1-MRN axis in the progression and aggressiveness of serous ovarian cancer. Berkel C; Cacan E Biochem Biophys Res Commun; 2021 Sep; 570():74-81. PubMed ID: 34273621 [TBL] [Abstract][Full Text] [Related]